Pharmacokinetic Optimization of Drug Candidates: Medicinal Chemistry Approaches for Improving Oral Bioavailability

Sinkyu Bell^*
*Correspondence: Sinkyu Bell, Department of Pharmaceutical Sciences, University of Salamanca, Salamanca, Spain, Email:

Introduction

The development of new therapeutic agents is a complex and multifaceted process that involves the identification of novel drug targets, the synthesis of lead compounds and the rigorous evaluation of their pharmacological properties. One of the most significant challenges in drug development is ensuring that these compounds can be effectively absorbed and distributed within the body to achieve their desired therapeutic effect. A key factor in this process is the oral bioavailability of the drug, which refers to the proportion of the administered dose that reaches the systemic circulation in an active form. Oral administration is the preferred route of drug delivery due to its convenience, ease of use and patient compliance, making it crucial to optimize the pharmacokinetic properties of drug candidates for oral bioavailability. Therefore, optimizing the pharmacokinetic properties of drug candidates, particularly their oral bioavailability, is a critical step in the drug discovery and development process. Medicinal chemistry offers a range of strategies and approaches to improve oral bioavailability, from modifying the chemical structure of compounds to utilizing innovative formulation techniques. This area of research has led to the development of more efficient and effective oral drugs that can provide better therapeutic outcomes for patients [1].

Description

Oral bioavailability is influenced by several factors, including the solubility of the drug, its permeability across biological membranes, its stability in the Gastrointestinal (GI) tract and its ability to resist metabolism by enzymes, especially those in the liver and intestines. For a drug to be absorbed efficiently after oral administration, it must first dissolve in the gastrointestinal fluids, then pass through the epithelial cells of the intestinal wall and enter the bloodstream. Once in the systemic circulation, the drug must be distributed to its site of action and remain active until its therapeutic effect is achieved. Throughout this process, various physiological barriers, such as the acidic environment of the stomach, the presence of efflux pumps in the intestinal wall and the metabolic activity of liver enzymes, can reduce the amount of drug that ultimately reaches its target. Therefore, medicinal chemists must carefully consider these factors when designing and optimizing drug candidates to ensure that they are not only effective in treating the intended condition but also have sufficient bioavailability to do so at therapeutic doses. Medicinal chemists can address this issue by modifying the chemical structure of the drug to increase its solubility, such as through the use of salt forms, prodrugs, or the incorporation of solubilizing groups. Additionally, the development of nanotechnology-based formulations, such as nanoparticles or lipid-based carriers, can improve the solubility and stability of drugs, enabling more efficient absorption [2].

Another important factor influencing oral bioavailability is the permeability of the drug across biological membranes. The gastrointestinal tract is lined with a lipid bilayer membrane that presents a barrier to the absorption of many drugs. To improve the permeability of drug candidates, medicinal chemists can modify the molecular structure to enhance lipophilicity, allowing the drug to better interact with the membrane and cross it more efficiently. In addition to solubility and permeability, drug metabolism is another critical factor that affects oral bioavailability. Many drugs undergo extensive first-pass metabolism in the liver and intestines, which can significantly reduce their bioavailability. This process involves enzymes such as cytochrome P450s, which metabolize drugs before they can reach their target tissues. To overcome this challenge, medicinal chemists can design drugs with improved resistance to metabolic degradation, either by modifying the chemical structure to avoid metabolic pathways or by using enzyme inhibitors that block specific metabolic enzymes. Alternatively, prodrug strategies can be employed, where the drug is initially administered in an inactive form that is metabolized into the active compound once it reaches its target site, thereby improving bioavailability [3].

Formulation strategies also play a vital role in enhancing the oral bioavailability of drugs. For example, the use of solid dispersions, where the drug is dispersed in a hydrophilic carrier, can improve solubility and dissolution rates. Similarly, the development of controlled-release formulations can help maintain therapeutic drug levels over an extended period, reducing fluctuations in drug concentrations and improving overall efficacy. Other approaches, such as the use of permeation enhancers or the incorporation of surfactants, can help to increase drug absorption by reducing barriers in the gastrointestinal tract. Finally, a more recent trend in optimizing oral bioavailability involves the use of drug delivery systems that exploit the body's natural transport mechanisms. For instance, receptor-mediated transport systems, such as the use of peptides or antibodies that can facilitate the transport of drugs across the intestinal epithelium, offer a novel approach to improving absorption. These systems take advantage of the body's own mechanisms to actively transport compounds across biological membranes, potentially overcoming limitations such as poor solubility or low permeability [4].

Furthermore, the development of personalized medicine offers a unique opportunity to optimize oral bioavailability on an individual basis. Genetic differences in drug-metabolizing enzymes, transporters and other pharmacokinetic factors can significantly affect how a person absorbs, distributes, metabolizes and eliminates drugs. By using pharmacogenomics and personalized approaches, medicinal chemists can tailor drug formulations to suit specific patient populations, improving bioavailability and minimizing side effects. For example, individuals with specific polymorphisms in cytochrome P450 enzymes may metabolize certain drugs more rapidly, requiring adjustments in the drug dose or formulation. Personalized drug delivery systems that account for individual variations in absorption and metabolism could ultimately lead to more effective treatments and better patient outcomes. Understanding a drugâ??s BCS classification allows for more rational drug design and ensures that the appropriate pharmacokinetic optimization strategies are employed. This approach helps to streamline the development process by focusing efforts on the most effective solutions for improving bioavailability based on the specific challenges posed by each drug candidate [5].

Conclusion

In conclusion, optimizing the oral bioavailability of drug candidates is a critical step in drug discovery and development, as it directly influences the therapeutic efficacy and safety of a drug. Medicinal chemistry approaches to improving bioavailability focus on addressing key barriers such as poor solubility, low permeability, extensive metabolism and formulation challenges. By employing a combination of strategies, including chemical modifications, formulation techniques and advanced drug delivery systems, medicinal chemists can enhance the chances of success for new drug candidates and provide more effective and accessible treatments for patients. As our understanding of pharmacokinetics continues to evolve and new technologies emerge, the development of drugs with optimized oral bioavailability will remain at the forefront of pharmaceutical research, offering the potential for improved patient outcomes and more convenient treatment options.

Acknowledgment

None.

Conflict of Interest

None.

References

1. EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Dominique Turck and Torsten Bohn, et al. "Conversion of calciumâ?lâ?methylfolate and (6S)â?5â?methyltetrahydrofolic acid glucosamine salt into dietary folate equivalents." EFSA J20 (2022): e07452.

Google Scholar        Cross Ref                Indexed at

2. Bhalani, Dixit V., Bhingaradiya Nutan, Avinash Kumar and Arvind K. Singh Chandel. "Bioavailability enhancement techniques for poorly aqueous soluble drugs and therapeutics." Biomedicines10 (2022): 2055.

Google Scholar        Cross Ref                Indexed at

3. Musther, Helen andres Olivares-Morales, Oliver JD Hatley and Bo Liu, et al. "Animal human oral drug bioavailability: Do they correlate?." Eur J Pharm Sci 57 (2014): 280-291.

Google Scholar        Cross Ref                Indexed at

4. Alshawwa, Samar Zuhair, Abeer Ahmed Kassem, Ragwa Mohamed Farid and Shaimaa Khamis Mostafa, et al. "Nanocarrier drug delivery systems: Characterization, limitations, future perspectives and implementation of artificial intelligence." Pharmaceutics14 (2022): 883.

Google Scholar        Cross Ref                Indexed at

5. Fedi, Arianna, Chiara Vitale, Giulia Ponschin and Seyoum Ayehunie, et al. "In vitro models replicating the human intestinal epithelium for absorption and metabolism studies: A systematic review." J Control Release 335 (2021): 247-268.

Google Scholar        Cross Ref                Indexed at